FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencel; ...

Calcium levels decreased less with each subsequent denosumab dose among individuals with osteoporosis and advanced chronic kidney disease.

Scientists conducted a simulation study to estimate the impact of cardiovascular-kidney-metabolic (CKM) syndrome on cardiovascular disease (CVD) risk prediction. The study found that adults with ...

Risk factors most closely tied to MetS include age as the likelihood increases with age, and a personal or family history of ...

ProKidney's REACT® therapy shows kidney function stabilization. Find out why PROK stock is risky due to cash issues and ...

Presented positive 96-week long-term eGFR stabilization data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in a late-breaking oral ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

The annual meeting of the American Society of Nephrology (Kidney Week) was held this year from Oct. 23 to 27 in San Diego, ...

Exposure to chemicals called PFAS during young adulthood has been linked to yet another serious health problem – reduced ...

Drugs for diabetic kidney disease treatment have greatly expanded, allowing research and consensus on their optimal use.

The following is a summary of “Multi-scalar data integration decoding risk genes for chronic kidney disease,” published in the October 2024 issue of Nephrology by Ding et al. Chronic Kidney Disease ...